18F-fluselenamyl

18F-fluselenamyl is a small molecule diagnostic radiopharmaceutical developed for positron emission tomography (PET) imaging of beta-amyloid plaques in the brain. It is labeled with fluorine-18 and designed to bind specifically to both diffuse and fibrillar amyloid-beta (Aβ) plaques, which are characteristic of Alzheimer's disease pathology. Unlike some existing tracers, 18F-fluselenamyl demonstrates high affinity and specificity for Aβ aggregates, including diffuse plaques that are present at prodromal stages of Alzheimer's disease. Preclinical studies have shown rapid brain penetration, favorable kinetics, and no significant pharmacological or toxicological effects in animal models. The agent is being evaluated for its safety profile and dosimetry in humans as a tool for early detection and monitoring of Alzheimer’s disease progression[2][3][5][6][8].

Other names

fluselenamyl[18F]-Fluselenamyl